The information on this page is intended for journalists, press and media. Click YES to get to the newsroom. If you click NO you will come back to Mynewsdesk.com.
ConceptoMed AS is delighted to announce a new partner for the Norwegian hospital market. We have entered into a distribution agreement with Vingmed AS granting exclusive rights for marketing, sales and distribution of the LuerJack syringes in the hospital market in Norway.
ConceptoMed AS has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LuerJack Slip syringes and the first LuerJack Lock 10ml syringe.
On the 14th of February 2017, the Chinese Patent and Trademark office issued an official document granting the Chinese patent for LuerJack. ConceptoMed’s strategy to protect our intellectual property rights (IPR) remains unchanged and strong. Along with other markets already protected, such as Europe, the US, Australia and Mexico, protection in Asia is now following.
ConceptoMed AS received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first size of the Luer-Jack® syringe.
In December 2016, ConceptoMed have entered into important collaborations with suppliers of sterilization services (Sterigenics) and logistics & healthcare warehousing services (DSV Logistics) to secure the global strategy for ConceptoMed and Luer-Jack.
On the 31st of August 2016, the European Patent Office issued an official document granting the European patent for Luer-Jack. IP Australia, the Australian Government agency that administers intellectual property (IP) rights and legislation relating to patents, issued an official document granting the Australian patent for Luer-Jack - also on the 31st of August 2016.
On the 10th of May 2016, the United States Patent and Trademark office issued an official document granting the US patent for Luer-Jack. The US Luer-Jack patent is an important part of the families of similar filed applications in all important markets world wide, and is a fundamental member of the Luer-Jack patent family.
The Board of Directors of ConceptoMed AS announce the final completion of the successful private placement of equity in ConceptoMed AS for the period January-February 2016. The placement round was oversubscribed.
ConceptoMed today hosted a very interesting and pleasant meeting with the Prime Minister of Norway, Erna Solberg We raised the question: With the healthcare worker's safety and patient safety in mind; do today's available disposable syringes and connectors fully enable healthcare providers to minimise occurrence of needlestick injuries and hospital acquired blood-borne infections?
The Norwegian Minister of Health Bent Høie will see how medical equipment in a simple and efficient way can increase quality for a large number of medical procedures. ConceptoMed is moving front stage to initiate and elevate focus on quality during the billions of small procedures being executed worldwide.
The Board of Directors of ConceptoMed AS have the pleasure of announcing the successful completion of a private placement of equity in ConceptoMed AS. The share issue was oversubscribed and provided the company with 12 new shareholders. Gross proceeds from the private placement amounted to NOK 11,550,000 (€1.42 Million)
The Board of ConceptoMed AS is pleased to announce the successful completion of a non-public offering. Gross proceeds from the Private Placement amount to NOK 5,005,000. The placement values the company at NOK 25 million.The process was opened at 18.00 CET Thursday 11 April 2013 and was completed at 15.00 CET Tuesday 16 April 2013. The company aquired 18 new shareholders, whereof 7 hav
On February 6, 2013, ConceptoMed AS was granted NOK 4 Million as support for further development of our innovations.
When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.
To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.
Please note that our Terms of Use apply to all use of our services.
You can withdraw your consent at any time by unsubscribing or deleting your account.
Email sent to __email__. Click the link there to follow ConceptoMed.
